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Abstract
Background The aim of this study was to analyze the safety and effectiveness of stenting using partially covered
self-expandable stents in palliation of dysphagia in patients with unresectable esophageal cancer.
Methods Retrospective analysis of hospital records of all patients who underwent esophageal stenting in the period
2008–2015 was performed. The study included patients with unresectable esophageal and esophagogastric cancer.
Results There were 442 patients included. Mean age was 56 years (range 28–89), and 379 were males. In 40 (9.0%)
patients, stenting was performed in the cervical, in 150 (39.3%)—in the middle thoracic, in 141 (31.9%)—in lower
thoracic esophagus and in 111 (25.1%)—in the esophagogastric junction. Stenting resulted in significant alleviation
of dysphagia grade (3.0 vs. 1.0, p = 0.00001). During the follow-up, 55 (12.4%) patients experienced recurrent
dysphagia due to tumor or granulation tissue overgrowth, and in 18 (4.1%) patients, migration of the stent occurred,
for which an independent risk factor was adjuvant chemo- and/or radiation therapy (p = 0.001). Minor complications
included chest pain (54.5%), delayed complete stent expansion (12.0%), feeling of a foreign body (25.3%), hiccup
(1.6%), gastroesophageal reflux (45.6%) and post-discharge pneumonia (2.5%). A feeling of a foreign body in the
esophagus was significantly more common after stenting of the cervical esophagus (p = 0.0001), and hiccup was
more common after stenting of the esophagogastric junction (p = 0.02). Major complications included bleeding
(1.3%), respiratory insufficiency (0.7%), esophageal perforation (0.9%) and irregular heartburn (2.3%). Overall
procedure-related mortality was 0.4%. The median survival time was 117.8 days (range 2–732).
Conclusions Stenting is an effective procedure in relieving dysphagia in patients with unresectable malignant eso-
phageal stenosis and is associated with low rate of postoperative and long-term complications.
Introduction
Squamous cell carcinoma of the esophagus is the eighth
most frequent cancer in the world, whereas carcinoma of
esophagogastric junction (OGJ) is the tumor with the
highest dynamics of incidence in the last two decades
[1–4].
It is estimated that in North America there are 5–10
cases of esophageal cancer per 100,000 inhabitants;
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however, depending on the geographical area, the inci-
dence may increase up to 100/100,000, such as in Iran
[5, 6].
Multimodal treatment consisting of preoperative
chemoradiation therapy followed by complete resection
and lymphadenectomy is a standard in therapeutic man-
agement. However, curative-intent treatment is possible in
only 20–40% of patients. In a majority of them, palliative
management is the only option, due to local advancement
and/or distant metastases [7]. In such cases, options of
palliative treatment include: chemo- and/or radiation ther-
apy, brachytherapy, stenting, laser ablation and photody-
namic therapy. Among them, stenting has a unique
advantage of immediate relief of dysphagia. Although
stenting is a safe and effective way to relieve the symptoms
of dysphagia and to improve the comfort of life, it is not
free from side effects, which may occur in the early and
late period after its implantation. Among the side effects,
mild symptoms can be distinguished, which do not require
intervention, but also life-threatening and fatal ones [8, 9].
In this study, we present one of the largest retrospective
analyses with prospective follow-up of patients with eso-
phageal cancer, who underwent esophageal stenting due to
unresectability of the tumor or medical inoperability. The
aim of this study was to evaluate the safety and efficacy of
stenting in patients with esophageal squamous cell carci-
noma and carcinoma of the esophagogastric junction,
complications, re-interventions and survival after the
treatment.
Materials and methods
This retrospective analysis of hospital records included
data of a consecutive group of patients with advanced
esophageal carcinoma, treated between 2008 and 2015 in
Department of Thoracic Surgery, Jagiellonian University
Collegium Medicum. Demographic and clinical data
including age, sex, weight, dysphagia, dyspnea,
chemotherapy/chemoradiation, technical success rate, stent
migration, complications and survival were evaluated.
Inclusion criteria
The study included all patients treated in the period
2008–2015 for unresectable or medically inoperable eso-
phageal or (OGJ) cancer, regardless of histological type.
Exclusion criteria
Exclusion criteria included:
• Preterminal condition, Karnofsky score B 40%;
• Patients with mediastinal infiltration causing dysphagia
in the course of lung cancer, lymphomas and other
malignancies.
Pre-treatment assessment
Unresectability was determined on the basis of chest
radiography, abdominal ultrasound, computed tomography
(CT) of the chest and the upper abdomen, positron-emis-
sion tomography (PET) and endoscopy, with the endo-
scopic ultrasound (EUS) and endobronchial ultrasound
(EBUS). Disease staging was based on the UICC classifi-
cation [10]. Dysphagia was assessed according to a four-
grade scale [11]:
• 0—no dysphagia;
• 1—swallowing of a semiliquid diet;
• 2—swallowing of a liquid diet;
• 3—dysphagia to the liquids and saliva.
Patients diagnosed with fistula in the course of esopha-
geal or bronchogenic cancer were classified into four
groups according to fistula location [12]:
• Type 1—fistula to the mediastinum;
• Type 2—fistula to the trachea;
• Type 3—fistula to the bronchus;
• Type 4—fistula after stenting.
Dyspnea severity was assessed with a four-grade scale
[12]:
• 0—less than 30% of tracheal or/and bronchial stenosis,
no dyspnea;
• 1—30–50% stenosis, dyspnea upon exercise;
• 2—50–70% stenosis, dyspnea during daily activities;
• 3—more than 70% stenosis, dyspnea while resting.
Patient performance status was assessed according to
Karnofsky score [13].
Intervention
Esophageal stenting was performed under general anes-
thesia. Location of the stenosis was endoscopically iden-
tified, and in case of narrow stenosis, dilatation was
performed with Savary–Gilliard dilators, up to the size of
10 Fr. After the dilatation, the neoplastic infiltration length
was assessed using a small-diameter endoscope, then a
guidewire was inserted and the esophageal stent was
introduced over it. Deployment of the stent was performed
under endoscopic control. Partially covered self-expand-
able metallic stents (70, 90 or 120 mm long and 18 mm
diameter, Ultraflex, Boston Scientific, Natick, MA, USA)
were used.
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Double stenting was performed in patients with unre-
sectable esophageal cancer involving the airway, with
dysphagia and dyspnea;
• Airway compression or infiltration posing the risk of
severe airway compromise after expansion of the
esophageal stent.
As a rule, airway stenting was performed before eso-
phageal stenting. The double stenting procedure was per-
formed under general anesthesia. The self-expandable
Ultraflex stents (Boston Scientific, Natick, MA, USA) were
used for stenting of fistulas to the trachea and silicone Y
stents (Demed, Mikołów, Poland) in case of fistula located
in the tracheal bifurcation and main bronchi. Stenting with
the use of silicone Y stents was performed using the Freitag
forceps according to the technique described elsewhere
[14].
Complications
Peri-, intra- and postoperative complications and any
additional procedures were recorded. Complications after
stenting were classified as minor or major. Minor compli-
cations were defined as those subsiding spontaneously or
following pharmacological treatment only, potentially
requiring endoscopy. All other, including life threatening
or fatal, were defined as major complications.
Postoperative complications were defined as early (oc-
curring within B 30 days following stenting) or late (oc-
curring later than[ 30 days following stenting).
Follow-up
Following the procedure, patients received a liquid diet the
same day. Routinely, on the first day after the procedure a
follow-up chest radiogram was obtained and dyspnea and
dysphagia scores were assessed. Patients received detailed
instructions regarding nutrition at discharge from the hos-
pital. Patients were followed up every 30 days thereafter. If
the follow-up visit in the clinic was not feasible, patients
were interviewed by phone. During the follow-up visit, the
patients’ general condition, dysphagia and dyspnea were
assessed.
Statistical analysis
Statistical analysis was performed using the STATISTICA
11 PL software package (StatSoft, Tulsa Oklahoma, USA).
The Mann–Whitney test was used to compare two samples.
Kruskal–Wallis test was used to compare three or more
attempts. In order to evaluate the changes over time (dys-
phagia before and after stenting, migration), the Wilcoxon
signed rank test was applied. To assess the significance of
connections between data on nominal scale, the Fisher’s
Chi-square test or Fisher’s exact test was used. The logistic
regression model was used to find the risk factors for
complications after stenting. If an important factor was
found, odds ratio (OR) was calculated along with 95%
confidence interval. Survival was calculated using Kaplan–
Meier method. Gehena–Wilcoxon test was used to compare
survival curves. p\ 0.05 was considered as statistically
significant.
Results
Characteristics of the study group
Between 2008 and 2015, 606 patients underwent esopha-
geal stenting for malignant esophageal obstruction. The
flowchart of the study is presented in Fig. 1. One hundred
and sixty-four patients who met the exclusion criteria were
excluded from this analysis, including:
• 46 patients with lung cancer;
• 2 patients with thyroid cancer;
• 1 patient with colorectal cancer;
• 1 patient with breast cancer;
• 7 patients with lymphomas;
• 45 due to the preterminal state or Karnofsky
score B 40%;
Fig. 1 Patients’ flowchart
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• 14 patients who were lost from postoperative follow-
up;
• 48 patients stented before planned surgical resection.
The final analysis included homogenous group of 442
patients with esophageal or OEJ cancer, who underwent
esophageal stenting procedure.
Patients presented with body weight loss from 4 to
40 kg, dysphagia, cough and cachexia. The mean length of
neoplastic infiltration in the esophagus was 5.9 cm (range
4–12 cm).
In 40 (9.0%) patients, stenting of the upper segment of
the esophagus was performed, including:
• 28 (6.3%) and 30 (6.34%) patients with the tumor
located between 18 and 21 cm from the incisors;
• 12 (2.7%) and 18 (4.16%) patients with the tumor
located between 22 and 25 cm from the incisors.
In 150 (39.3%) patients, stenting was performed in the
middle part of the esophagus, in 141 (31.9%)—in the lower
thoracic part of the esophagus and in 111 (25.1%)—in the
OGJ.
Nineteen (4.3%) patients had primary fistula to the
mediastinum or the airway. Fifteen (3.04%) patients with
fistula developed after the stenting procedure. Adjuvant
chemo- and radiation therapy was administered to 201
(45.5%) patients (Table 1).
Technical success
Stenting procedure could not be performed in 3 (0.6%)
patients due to complete obstruction of the esophagus.
These patients underwent laparotomy and gastrostomy.
Thus, the technical success rate was 99.4%.
Dysphagia relief
After stenting procedure, swallowing improvement was
observed in all the patients. The mean dysphagia score
improved from 3.0 (range 2–3) before stenting to 1 (range
1–2) after the stenting procedure (p = 0.00001).
Early complications
Minor complications
After esophageal stenting, 241 (54.5%) patients reported
chest pain: in 28 (6.3%) patients with stent in the proximal
esophagus, in 94 (21.2%)—in the middle part, in 78
(17.6%)—in the lower part and in 49 (11.0%)—in the EGJ.
Pain occurred more frequently in patients with stents the
proximal and middle part of the esophagus (p = 0.004). In
209 (42.3%) patients, mild analgesia was required and the
pain subsided within 2–4 days after the procedure, whereas
in 33 (7.5%) patients long-term analgetic medication was
needed.
Incomplete immediate stent expansion occurred in 53
(12.0%) patients. In all of them, the stent expanded fully
without any intervention within 48 h.
Difficulties in swallowing, associated with the feeling of
a foreign body, were reported by 112 (25.3%) patients,
including 29 (6.6%) with a stent in the proximal esophagus,
30 (6.8%)—in the middle part, in 21 (4.8%)—in the lower
part and in 29 (5.7%) of them after the stenting of OGJ.
The feeling of a foreign body was present only in patients
with stents in the proximal part of the esophagus
(p = 0.0001). These symptoms subsided completely or
partially within 3–7 days.
Table 1 Demographic and clinical characteristics of the study group
Characteristics of the study population Number of patients (no/%)
Sex (male/female) 442 (379/63)
Mean age (range), (years) 59 (35–82)
Histopathology
SCC 331 (74.9%)
OGJ 111 (25.1%)
Location
Upper esophagus 40 (9.1%)
Middle esophagus 150 (33.9%)
Lower esophagus 141 (31.9%)
Esophagogastric junction 111 (25.1%)
Dysphagia score
Grade 1 0
Grade 2 389 (88.0%)
Grade 3 53 (12.0%)
Esophago-airway fistula (OAF) 34 (7.7%)
Type 1 7 (1.6%)
Type 2 4 (0.9%)
Type 3 8 (1.8%)
Type 4 15 (3.4%)
Treatment after stenting 201 (45.5)
CTH 51 (11.5)
RTH 17 (3.8)
CTH/RTH 131 (29.6)
BTH 2 (0.4)
Median survival time (range) 117.8 (2–732)
SCC 131.2 (2–732)
OGJ cancer 109.8 (38–221)
OAF 74.5 (41–432)
CTH chemotherapy, RTH radiotherapy, CTH/RTH chemo and radio-
therapy, BTH brachytherapy, OAF esophago-airway fistula, SCC
squamous cell carcinoma, OGJ esophagogastric junction
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Hiccup occurred in 7 (1.6%) patients after esophageal
stenting: In 4 of them, it happened after stenting of the EGJ
and required stent removal in 3 cases, and in 3 (0.7%)
patients after stenting of the lower part of the thoracic
esophagus (p = 0.02), requiring stent removal in 1 (0.2%)
patient. In 3 patients with squamous cell carcinoma and in
4 with OGJ, carcinoma early migration of the stent
occurred. Two hundred and two (45.6%) patients reported
reflux symptoms, and they required treatment with proton-
pump inhibitors. After discharge from the hospital, in 11
(2.5%) patients pneumonia occurred and they received
outpatient treatment.
Major complications
Immediately after the stenting, bleeding occurred in 6
(1.3%) patients, and in 3 (0.7%) of them, transfusion of 2–4
units of packed red blood cells was necessary.
Irregular heartburn occurred in 10 (2.3%) patients
(Table 2). Symptoms of respiratory insufficiency requiring
mechanical ventilation for 2–4 days occurred in 3 (0.7%)
patients. In all these patients, respiratory function improved
and ventilatory support was discontinued. In 4 (0.9%)
patients, perforation of the esophageal wall occurred during
the pre-stenting dilatation. In 2 (0.4%) patients, it happened
in the middle part and in 2 (0.4%) patients in the lower part
of the esophagus. All these patients were treated conser-
vatively. Three of them (0.7%) recovered, and one (0.2%)
patient died. Another patient died directly after the stenting
due to heart arrhythmia not responding neither to phar-
macological nor to electrical therapy. Thus, the overall
procedure-related mortality was 0.4%.
Late complications
Re-interventions
In 18 (4.1%) patients, migration of the stent occurred. It
happened in the middle thoracic part of the esophagus in 3
(0.7%) the patients, in the lower part in 7 (1.6%) patients
and in 8 (1.8%) patients in the OGJ (p = 0.06) (Table 2).
Adjuvant treatment with CTH and/or RTH was a risk factor
for stent migration [p = 0.001; OR 6.08 (95% CI
2.01–5.83)]. There were no significant differences in the
migration rates when SCC was compared with adenocar-
cinoma of the OGJ (p = 0.06).
In 7 patients with squamous cell carcinoma and in 4
with OGJ carcinoma, late migration of the stent occurred.
Table 2 Complications of stenting
Complication after stenting SCC OGJ p value
Migration 10 (2.0%) 8 (1.8%)
Partial—no re-stenting 1 (0.2%) 1 (0.2%)
Complete (no re-stenting) 1 (0.2%) 0
Complete (re-stenting) 8 (1.8%) 7 (1.42%) 0.06
Restenosis 39 (7.92%) 16 (3.6%)
Granulation—proximal end of the stent 32 (7.2%) 14 (3.1%)
Granulation—distal end of the stent 5 (1.1%) 2 (0.4%)
Malignant obstruction 2 (0.4%) 0 0.54
Re-stenting 45 (10.1%) 23 (5.2%)
Stent removal and re-stenting 16 (3.6%) 10 (2.2%)
Telescope stenting 15 (3.4%) 4 (0.9%)
Re-stenting with one stent 14 (3.1%) 9 (2.0%)
Airway stenosis 4 (0.9%) 0
Critical—airway stenting 2 (0.4%) 0
Non-critical—observation 2 (0.4%) 0
Perforation 3 (0.7%) 0
OAF 34 (7.7%) 0
Primary 19 (4.3%
After stenting 15 (3.4%)
Respiratory failure 3 (0.7%) 0
Death 2 (0.4%) 0
OAF esophago-airway fistula, SCC squamous cell carcinoma, OGJ esophagogastric junction
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Dysphagia associated with stent obliteration by the
ingrowing granulation tissue occurred in 55 (12.4%)
patients: in 46 (10.4%) at the proximal end of stent and in 9
(2.0%) patients at the distal end. In 2 (0.4%) patients,
ingrowing tumor was observed. Development of granula-
tion tissue was observed in the period from 27 to 103 days
(mean 72 days) since stent implantation. In 5 (1.1%)
patients, ingrowing granulation tissue was observed in the
proximal part of the esophagus, in 16 (3.6%) patients in the
middle part, in 19 (4.3%) patients in the lower part and in
16 (3.6%) patients in the EGJ (p = 0.54). In patients with
stent obliteration by tumor or granulation tissue ingrowth,
restoration of patency was performed with the use of argon
plasma coagulation followed by re-stenting.
Stent removal and re-stenting procedure were required
in 28 (6.3%) and 31 (6.3%) patients, respectively. Forty-six
(10.4%) patients with stent obstruction received CTH and/
or RTH, which was a risk factor for stent obstruction
[p = 0.00006; OR 3.42 (95% CI 2.01–5.83)].
In 4 (0.9%) patients, esophageal stenting resulted in
compression of the airway. In 2 (0.4%) of them, symptoms
of dyspnea required additional stenting of the bronchial
tree with Y stent; in the remaining 2 (0.4%) patients,
compression of the bronchial tree\ 30% of lumen occur-
red, without symptoms of dyspnea and not requiring
additional stenting. These patients were subjected to fol-
low-up (Table 3).
Survival
The follow-up period ranged between 1 and 732 days.
Median survival time was 117.8 days (range 2–732)
(Fig. 2). Median survival time was longer in patients with
SCC than with adenocarcinoma: 158 (range 2–732) versus
110 (range 38-221) days (p = 0.06). Median survival time
in patients with OAF was 74.5 days (range 41–432).
Esophago-airway fistula
Esophago-airway fistula (OAF) was found in 34 (7.7%)
patients (Table 1). Nineteen (4.3%) patients had OAF at
presentation, and in 15 patients, it developed after stenting.
Among all 34 patients with OAF, it developed in 26 (5.9%)
patients after double stenting (esophagus and airway) and
in 8 patients after esophageal stenting only. In all those
patients, improvement in dysphagia score (2.81 vs. 1.3,
p = 0.0001 and 2.68 vs. 1.0, p = 0.0001), dyspnea score
(2.85 vs. 0.36, p = 0.001 and 1.69 vs. 0.08, p = 0.0001)
and Karnofsky score (59 vs. 70, p = 0.0001) was achieved.
There was no significant improvement in BMI (18.48 vs.
18.39, p = 0.6). The median survival after stenting of the
OAF was 74.5 days (range 41–432) days. The survival did
not correlate with the use of chemotherapy or chemoradi-
ation (p = 0.54).
Table 3 Interventional management
Complication after stenting SCC OGJ Secondary p value
Migration 10 (2.03%) 8 (1.62%) 2 (0.4%)
Partial—no re-stenting 1 (0.2%) 1 (0.2%)
Complete—no re-stenting 0 0 1 (1.42%)
Complete—re-stenting 9 (1.82%) 7 (1.6%)(1.42%) 1 (1.42%) p = 0.6
Restenosis 39 (7.92%) 16 (3.25%) 4 (0.81%)
Granulation—proximal end of the stent 32 (6.5%) 14 (2.84%) 3 (3.4%)
Granulation—distal end of the stent 5 (1.01%) 2 (0.4%) 1 (1.41%)
Malignant obstruction 2 (0.4%) 0 p = 0.54
Re-stenting 52 (10.56%) 17 (3.45%)
Stent removal 22 (4.47%) 9 (1.82%)
Telescope stenting 30 (6.09%) 8 (1.62%)
Airway stenosis 10 (2.03%)
Critical—airway stenting 6 (1.21%)
Non-critical—observation 4 (0.81%)
Perforation 3 (0.6%)
OAF 15 (3.04%)
Respiratory failure 3 (0.6%)
Death 2 (0.4%)
OAF esophago-airway fistula, SCC squamous cell carcinoma, OGJ esophagogastric junction
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Discussion
A primitive stent was used for the first time for intubation
of the esophageal stenosis in 1885, and rapid development
of stenting occurred together with the development of
endoscopy [5, 15]. In the 1970s and 1980s, rigid and
semirigid stents were used, and since the 1990s, non-cov-
ered, partially covered and fully covered self-expandable
stents have been available. Despite technological
advancements and simplicity of implantation, their use is
not free from life-threatening complications [8, 16, 17].
Stenting in inoperable esophageal cancer is an attractive
alternative to surgical gastro-jejunostomy, enabling oral
nutrition, improvement in metabolic status and comfort of
life, but also allowing complementary treatment (chemo
and/or chemo-radiotherapy). It is a relatively simple pro-
cedure; however, due to the anatomical relationship of the
esophagus to the bronchial tree, possible complications and
re-interventions after stenting, this treatment should be
planned in reference centers.
One of the most frequent complications of esophageal
stenting is ingrowth or overgrowth of granulation tissue or
tumor at the ends of the stent. In our study, the percentage
of tissue overgrowth was 11.99%, with the applied stenting
margin of 4 cm. These results are consistent with the lit-
erature data, showing its incidence of 4–47% (higher in
cases of the use of non-covered stents) [17, 18]. Results are
much better if covered stents are used: Ingrowth of gran-
ulation tissue can occur only at the uncovered ends of the
stent. Reportedly, it was observed in 3–18% of cases
[19–22] which, again, corresponds with our results. The
mechanism of overgrowth of granulation tissue is not
precisely known, but according to some authors it grows
more slowly in stents with lumen diameter of 18 mm [23].
This was, however, not confirmed in other studies using
stents with wide diameter of 23 mm [24, 25].
The second most frequent complication is stent migra-
tion, which reportedly occurs in 0–20% cases [21–23]. Our
results confirm the finding of chemotherapy or chemora-
diation as an independent risk factor for migration. In the
randomized study on stenting in unresectable gastric can-
cer, Lee et al. observed statistically significant differences
in migration and obstruction for uncovered stents com-
pared to covered stents (9.5 vs. 5.4 and 7.1 vs. 37.8%) [26].
Van den Berg et al. [27] performed stenting procedures of
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OAF and of postoperative anastomotic leaks using the
23 mm stents and did not confirm their superiority
regarding risk of migration. In a randomized study,
Siersma et al. demonstrated that 12 out of 13 migrations
were associated with smaller stent diameter and only one
was associated with larger diameter of the stent [28]. As we
only used 18-mm-wide stents, we could not analyze the
impact of stent diameter on the risk of migration. On the
other hand, the use of stents of larger diameter can be
associated with a higher rate of perforations and bleeding
[23]. Sgourakis et al. [29] did not observe an advantage of
any kind of stents with regard to complications and reflux,
even in cases of application of stents with antireflux valves.
Based on the analysis of a group of 332 patients, Park et al.
observed that stenting of an obstruction present in the area
of EGJ and the administration of adjuvant chemoradiation
therapy were independent risk factors for migration [30].
Also, the stents with anti-migration mechanism (SX Ella,
Niti S, Alimaax) do not always prevent migration effec-
tively [19, 31]. In our series, we did not find significant
difference in migration rate regarding location of the stent.
Although esophageal stenting is characterized by a very
high technical success rate, it is associated with the risk of
life-threatening complications. One of them is development
of an OAF following the procedure. According to the lit-
erature, it occurs in up to 10% of patients after the stenting
procedure. Ferreira et al. reported the occurrence of such
fistulas in 7 out of 126 treated patients and Uitdehaag et al.
in 2 out of 44 patients, after the application of SX Ella
stents with anti-migration mechanism [20, 32]. In our
group, OAF occurred after stenting in 15 (3.4%) patients.
Other most frequent severe complications include:
hemorrhage, which occurs in 2–28%, perforations, peri-
operative mortality, which was estimated to be 0.5–7%,
and a 30-day mortality that ranges from 7 to 18%
[20, 23, 32–37]. In our series, bleeding occurred in 6
(1.3%) patients, perforation in 3 (0.7%), perioperative
mortality in 2 (0.4%) and 30-day mortality in 3 (0.7%).
These results compare favorably with the literature data.
Esophageal stenting may enable the introduction of
chemotherapy or chemoradiation. Chemotherapy enables
relief of dysphagia and full oral nutrition, so the European
Society of Gastrointestinal Endoscopy recommends its
administration [38, 39]. There is no clear statement whe-
ther it should be introduced before the stenting or after it.
Also, adjuvant therapy is associated with risk of life-
threatening complications [38–40]. Yakami et al. reported
a case of death as a result of fistula between the esophagus
and the left atrium, which occurred after radiation therapy.
The author suggests the application of stenting procedure
in patients who do not respond to chemotherapy or
chemoradiation [41]. Park et al. reported that the admin-
istration of adjuvant therapy is an independent risk factor
for the occurrence of stent migration and obstruction [30].
In our series, chemotherapy or chemoradiation was asso-
ciated with higher risk factor for stent migration and stent
obstruction.
Generally, the use of partially covered self-expandable
metallic stents in inoperable/unresectable esophageal can-
cer is safe and effective palliative procedure, with low rate
of complications and perioperative mortality.
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